| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1999;100:1602-1608.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Assessment of the Treatment Effect of Enoxaparin for Unstable Angina/Non–Q-Wave Myocardial Infarction
TIMI 11B–ESSENCE Meta-Analysis
From the Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital (E.M.A., C.H.M., E.B.), Boston, Mass; Hahnemann University Hospital (M.C.), Philadelphia, Pa; and Rhône-Poulenc Rorer (D.R., J.R., J.P.), Collegeville, Pa. Rhône-Poulenc Rorer manufactures Lovenox (enoxaparin).
Correspondence to Elliott M. Antman, MD, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. E-mail eantman{at}rics.bwh.harvard.edu
Background—Two phase III trials of enoxaparin for unstable angina/non–Q-wave myocardial infarction have shown it to be superior to unfractionated heparin for preventing a composite of death and cardiac ischemic events. A prospectively planned meta-analysis was performed to provide a more precise estimate of the effects of enoxaparin on multiple end points.
Methods and Results—Event rates for death, the composite end points of death/nonfatal myocardial infarction and death/nonfatal myocardial infarction/urgent revascularization, and major hemorrhage were extracted from the TIMI 11B and ESSENCE databases. Treatment effects at days 2, 8, 14, and 43 were expressed as the OR (and 95% CI) for enoxaparin versus unfractionated heparin. All heterogeneity tests for efficacy end points were negative, which suggests comparability of the findings in TIMI 11B and ESSENCE. Enoxaparin was associated with a 20% reduction in death and serious cardiac ischemic events that appeared within the first few days of treatment, and this benefit was sustained through 43 days. Enoxaparin's treatment benefit was not associated with an increase in major hemorrhage during the acute phase of therapy, but there was an increase in the rate of minor hemorrhage.
Conclusions—The accumulated evidence, coupled with the simplicity of subcutaneous administration and elimination of the need for anticoagulation monitoring, indicates that enoxaparin should be considered as a replacement for unfractionated heparin as the antithrombin for the acute phase of management of patients with high-risk unstable angina/non–Q-wave myocardial infarction.
Key Words: enoxaparin • heparin • meta-analysis • anticoagulants
This article has been cited by other articles:
 |
|
 |
|
  A. Kumar and C. P. Cannon Acute Coronary Syndromes: Diagnosis and Management, Part I Mayo Clin. Proc., October 1, 2009; 84(10): 917 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Bonaca, P. G. Steg, L. J. Feldman, J. F. Canales, J. J. Ferguson, L. Wallentin, R. M. Califf, R. A. Harrington, and R. P. Giugliano Antithrombotics in acute coronary syndromes. J. Am. Coll. Cardiol., September 8, 2009; 54(11): 969 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J M Wilson Diagnosis and treatment of acquired coronary artery disease in adults Postgrad. Med. J., July 1, 2009; 85(1005): 364 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Hollenberg Acute Coronary Syndromes ACCP Crit Care Med Brd Rev, January 1, 2009; 20(0): 129 - 144. [Full Text] [PDF]
|
|
|
|
 |
|
 J. C Coons and S. Battistone 2007 Guideline Update for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction: Focus on Antiplatelet and Anticoagulant Therapies Ann. Pharmacother., July 1, 2008; 42(7): 989 - 1001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Albert, N. Halevy, and E. M. Antman Preoperative Evaluation for Cardiac Surgery Card. Surg. Adult, January 1, 2008; 3(2008): 261 - 280. [Full Text]
|
|
|
|
|
|
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF]
|
|
|
|
 |
|
 K. P. Alexander, L. K. Newby, C. P. Cannon, P. W. Armstrong, W. B. Gibler, M. W. Rich, F. Van de Werf, H. D. White, W. D. Weaver, M. D. Naylor, et al. Acute Coronary Care in the Elderly, Part I: Non-ST-Segment-Elevation Acute Coronary Syndromes: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology Circulation, May 15, 2007; 115(19): 2549 - 2569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. De Caterina, S. Husted, L. Wallentin, G. Agnelli, F. Bachmann, C. Baigent, J. Jespersen, S. D. Kristensen, G. Montalescot, A. Siegbahn, et al. Anticoagulants in heart disease: current status and perspectives Eur. Heart J., April 10, 2007; (2007) ehl492v1. [Full Text] [PDF]
|
|
|
|
|
|
M. Cohen, K. W. Mahaffey, K. Pieper, C. V. Pollack Jr, E. M. Antman, J. Hoekstra, S. G. Goodman, A. Langer, J. J. Col, H. D. White, et al. A Subgroup Analysis of the Impact of Prerandomization Antithrombin Therapy on Outcomes in the SYNERGY Trial: Enoxaparin Versus Unfractionated Heparin in Non-ST-Segment Elevation Acute Coronary Syndromes J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1346 - 1354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. O. Adesanya, J. A. de Lemos, N. B. Greilich, and C. W. Whitten Management of perioperative myocardial infarction in noncardiac surgical patients. Chest, August 1, 2006; 130(2): 584 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Part 8: Stabilization of the Patient With Acute Coronary Syndromes Circulation, December 13, 2005; 112(24_suppl): IV-89 - IV-110. [Full Text] [PDF]
|
|
|
|
|
|
Part 5: Acute Coronary Syndromes Circulation, November 29, 2005; 112(22_suppl): III-55 - III-72. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Aazami Initial Appraisal of Acute Coronary Syndromes Journal of Pharmacy Practice, October 1, 2005; 18(5): 377 - 393. [Abstract] [PDF]
|
|
|
|
 |
|
 G. R. Hetzel and C. Sucker The heparins: all a nephrologist should know Nephrol. Dial. Transplant., October 1, 2005; 20(10): 2036 - 2042. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Di Nisio, S. Middeldorp, and H. R. Buller Direct Thrombin Inhibitors N. Engl. J. Med., September 8, 2005; 353(10): 1028 - 1040. [Full Text] [PDF]
|
|
|
|
 |
|
 H. U. Jones, J. B. Muhlestein, K. W. Jones, D. G. Renlund, T. L. Bair, T. J. Bunch, B. D. Horne, D. L. Lappe, J. L. Anderson, and D. B. Doty Early Postoperative Use of Unfractionated Heparin or Enoxaparin is Associated with Increased Surgical Re-Exploration for Bleeding Ann. Thorac. Surg., August 1, 2005; 80(2): 518 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. B. Gibler, C. P. Cannon, A. L. Blomkalns, D. M. Char, B. J. Drew, J. E. Hollander, A. S. Jaffe, R. L. Jesse, L. K. Newby, E. M. Ohman, et al. Practical Implementation of the Guidelines for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction in the Emergency Department: A Scientific Statement From the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in Collaboration With the Society of Chest Pain Centers Circulation, May 24, 2005; 111(20): 2699 - 2710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G A Large Contemporary management of acute coronary syndrome Postgrad. Med. J., April 1, 2005; 81(954): 217 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Harrington, R. C. Becker, M. Ezekowitz, T. W. Meade, C. M. O'Connor, D. A. Vorchheimer, and G. H. Guyatt Antithrombotic Therapy for Coronary Artery Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 513S - 548S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P R Sinnaeve and F J Van de Werf Will oral antithrombin agents replace warfarin? Heart, August 1, 2004; 90(8): 827 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 SYNERGY Trial Investigators Enoxaparin vs Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Managed With an Intended Early Invasive Strategy: Primary Results of the SYNERGY Randomized Trial JAMA, July 7, 2004; 292(1): 45 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Blazing, J. A. de Lemos, H. D. White, K. A. A. Fox, F. W. A. Verheugt, D. Ardissino, P. M. DiBattiste, J. Palmisano, D. W. Bilheimer, S. M. Snapinn, et al. Safety and Efficacy of Enoxaparin vs Unfractionated Heparin in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Who Receive Tirofiban and Aspirin: A Randomized Controlled Trial JAMA, July 7, 2004; 292(1): 55 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Petersen, K. W. Mahaffey, V. Hasselblad, E. M. Antman, M. Cohen, S. G. Goodman, A. Langer, M. A. Blazing, A. Le-Moigne-Amrani, J. A. de Lemos, et al. Efficacy and Bleeding Complications Among Patients Randomized to Enoxaparin or Unfractionated Heparin for Antithrombin Therapy in Non-ST-Segment Elevation Acute Coronary Syndromes: A Systematic Overview JAMA, July 7, 2004; 292(1): 89 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Das and D. J. Moliterno Fractionating Heparins and Their Clinical Trial Data--Something for Everyone JAMA, July 7, 2004; 292(1): 101 - 103. [Full Text] [PDF]
|
|
|
|
|
|
Q. Hu and J. O. Brady Recombinant Activated Factor VII for Treatment of Enoxaparin-Induced Bleeding Mayo Clin. Proc., June 1, 2004; 79(6): 827 - 827. [PDF]
|
|
|
|
 |
|
 A. Gamba, M. Merlo, R. Fiocchi, A. Terzi, C. Mammana, R. Sebastiani, and P. Ferrazzi Heart transplantation in patients with previous Fontan operations J. Thorac. Cardiovasc. Surg., February 1, 2004; 127(2): 555 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Bijsterveld, R. J. G. Peters, S. A. Murphy, P. J. L. M. Bernink, J. G. P. Tijssen, M. Cohen, and TIMI 11B/ESSENCE Study Groups Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: Results from the thrombolysis in myocardial infarction (TIMI) 11B and efficacy and safety of subcutaneous enoxaparin in Non-Q-Wave coronary events (ESSENCE) studies J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2083 - 2089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Medalion, G. Frenkel, P. Patachenko, E. Hauptman, L. Sasson, and A. Schachner Preoperative use of enoxaparin is not a risk factor for postoperative bleeding after coronary artery bypass surgery J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1875 - 1879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Braunwald Application of Current Guidelines to the Management of Unstable Angina and Non-ST-Elevation Myocardial Infarction Circulation, October 21, 2003; 108(90161): III-28 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Aronow Review Article: Treatment of Unstable Angina Pectoris/Non-ST-Segment Elevation Myocardial Infarction in Elderly Patients J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2003; 58(10): M927 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gupta, W.-C. Chang, F. Van de Werf, C. B. Granger, W. Midodzi, G. Barbash, K. Pehrson, A. Oto, P. Toutouzas, P. Jansky, et al. International differences in in-hospital revascularization and outcomes following acute myocardial infarction: A multilevel analysis of patients in ASSENT-2 Eur. Heart J., September 2, 2003; 24(18): 1640 - 1650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Kincaid, M. L. Monroe, D. L. Saliba, N. D. Kon, W. G. Byerly, and M. G. Reichert Effects of preoperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting Ann. Thorac. Surg., July 1, 2003; 76(1): 124 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Cannon and A. G.G. Turpie Unstable Angina and Non-ST-Elevation Myocardial Infarction: Initial Antithrombotic Therapy and Early Invasive Strategy Circulation, June 3, 2003; 107(21): 2640 - 2645. [Full Text] [PDF]
|
|
|
|
|
|
M. Cohen The role of low-molecular-weight heparin in the management of acute coronary syndromes J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 55S - 61S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. McKay "Ischemia-guided" versus "early invasive" strategies in the management of acute coronary syndrome/non-ST-segment elevation myocardial infarction: The interventionalist's perspective J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 96S - 102S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Goodman, D. Fitchett, P. W. Armstrong, M. Tan, A. Langer, and for the Integrilin and Enoxaparin Randomized Asses Randomized Evaluation of the Safety and Efficacy of Enoxaparin Versus Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Receiving the Glycoprotein IIb/IIIa Inhibitor Eptifibatide Circulation, January 21, 2003; 107(2): 238 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Wong, R. P. Giugliano, and E. M. Antman Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention JAMA, January 15, 2003; 289(3): 331 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Collet, G. Montalescot, E. Fine, J.-L. Golmard, M. Dalby, R.e. Choussat, A. Ankri, R. Dumaine, C. Lesty, N. Vignolles, et al. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials J. Am. Coll. Cardiol., January 1, 2003; 41(1): 8 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Bertrand, M. L. Simoons, K. A.A. Fox, L. C. Wallentin, C. W. Hamm, E. McFadden, P. J. De Feyter, G. Specchia, and W. Ruzyllo Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Eur. Heart J., December 1, 2002; 23(23): 1809 - 1840. [Full Text] [PDF]
|
|
|
|
|
|
C.P. Cannon A reply Eur. Heart J., October 2, 2002; 23(20): 1633 - 1634. [Full Text] [PDF]
|
|
|
|
|
|
S. James, P. Armstrong, R. Califf, S. Husted, F. Kontny, M. Niemminen, M. Pfisterer, M.L. Simoons, and L. Wallentin Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes Eur. Heart J., October 1, 2002; 23(19): 1538 - 1545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. U. Jones, J. B. Muhlestein, K. W. Jones, T. L. Bair, F. Lavasani, M. Sohrevardi, B. D. Horne, D. Doty, and D. L. Lappe Preoperative Use of Enoxaparin Compared With Unfractionated Heparin Increases the Incidence of Re-Exploration for Postoperative Bleeding After Open-Heart Surgery in Patients Who Present With an Acute Coronary Syndrome: Clinical Investigation and Reports Circulation, September 24, 2002; 106(12_suppl_1): I-19 - I-22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Borja, J. Curto, J. Campbell, and M. A. Paz Enoxaparin after high-risk coronary stenting J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1197 - 1198. [Full Text] [PDF]
|
|
|
|
|
|
E.M. Antman 'I can see clearly now': a new view on the use of IV GP IIb/IIIa inhibitors in acute coronary syndromes Eur. Heart J., September 2, 2002; 23(18): 1408 - 1411. [Full Text] [PDF]
|
|
|
|
|
|
C. K. Dyke, R. C. Becker, N. S. Kleiman, J. S. Hochman, E. G. Bovill, A. M. Lincoff, G. Gerstenblith, V. Dzavik, L. H. Gardner, V. Hasselblad, et al. First Experience With Direct Factor Xa Inhibition in Patients With Stable Coronary Disease: A Pharmacokinetic and Pharmacodynamic Evaluation Circulation, May 21, 2002; 105(20): 2385 - 2391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.J. Ferguson Antithrombin therapy, antiplatelet therapy and percutaneous coronary intervention: rationale and design of the SYNERGY trial Eur. Heart J. Suppl., May 1, 2002; 4(suppl_E): E2 - E9. [Abstract] [PDF]
|
|
|
|
|
|
C. P. Cannon Primary Percutaneous Coronary Intervention for All? JAMA, April 17, 2002; 287(15): 1987 - 1989. [Full Text] [PDF]
|
|
|
|
|
|
C.P. Cannon Enoxaparin in ST elevation MI--a bright future Eur. Heart J., April 2, 2002; 23(8): 591 - 592. [Full Text] [PDF]
|
|
|
|
|
|
S.H. Baird, I.B.A. Menown, S.J. Mcbride, T.G. Trouton, and C. Wilson Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction Eur. Heart J., April 2, 2002; 23(8): 627 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Ageno and A. G.G. Turpie New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins Can. Med. Assoc. J., April 1, 2002; 166(7): 919 - 924. [Full Text] [PDF]
|
|
|
|
|
|
J.J. Ferguson Moving beyond unfractionated heparin for acute coronary syndromes: Xeno's Paradox revisited Eur. Heart J., February 2, 2002; 23(4): 264 - 268. [Full Text] [PDF]
|
|
|
|
|
|
E.M. Antman, M. Cohen, C. McCabe, S.G. Goodman, S.A. Murphy, and E. Braunwald Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE Eur. Heart J., February 2, 2002; 23(4): 308 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. A. Fox, S. G. Goodman, J. A. Cairns, and P. Theroux Enoxaparin Treatment in Unstable Coronary Artery Disease : International Cost Savings Chest, February 1, 2002; 121(2): 666 - 667. [Full Text] [PDF]
|
|
|
|
|
|
R. Corti, V. Fuster, and J.J. Badimon Strategy for ensuring a better future for the vessel wall Eur. Heart J. Suppl., February 1, 2002; 4(suppl_A): A31 - A41. [Abstract] [PDF]
|
|
|
|
|
|
Randomized, Placebo-Controlled Trial of Titrated Intravenous Lamifiban for Acute Coronary Syndromes Circulation, January 22, 2002; 105(3): 316 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. B. Batchelor, K. W. Mahaffey, P. B. Berger, E. Deutsch, S. Meier, V. Hasselblad, E. T. Fry, P. S. Teirstein, A. M. Ross, C. A. Binanay, et al. A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial J. Am. Coll. Cardiol., November 15, 2001; 38(6): 1608 - 1613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hirsh, S. S. Anand, J. L. Halperin, and V. Fuster Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association Arterioscler Thromb Vasc Biol, July 1, 2001; 21 (7): e9 - e9. [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. G. Turpie and E. M. Antman Low-Molecular-Weight Heparins in the Treatment of Acute Coronary Syndromes Arch Intern Med, June 25, 2001; 161(12): 1484 - 1490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Cannon, W. S. Weintraub, L. A. Demopoulos, R. Vicari, M. J. Frey, N. Lakkis, F.-J. Neumann, D. H. Robertson, P. T. DeLucca, P. M. DiBattiste, et al. Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban N. Engl. J. Med., June 21, 2001; 344(25): 1879 - 1887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hirsh, S. S. Anand, J. L. Halperin, and V. Fuster Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association Circulation, June 19, 2001; 103(24): 2994 - 3018. [Full Text] [PDF]
|
|
|
|
|
|
S. G. Goodman and A. Langer Reply J. Am. Coll. Cardiol., June 1, 2001; 37(7): 2007 - 2008. [Full Text] [PDF]
|
|
|
|
|
|
E. M. Antman The Search for Replacements for Unfractionated Heparin Circulation, May 8, 2001; 103(18): 2310 - 2314. [Full Text] [PDF]
|
|
|
|
|
|
G. N. Levine, M. N. Ali, and A. I. Schafer Antithrombotic Therapy in Patients With Acute Coronary Syndromes Arch Intern Med, April 9, 2001; 161(7): 937 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ph. Collet, G. Montalescot, L. Lison, R. Choussat, A. Ankri, G. Drobinski, I. Sotirov, and D. Thomas Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris Circulation, February 6, 2001; 103(5): 658 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
British Cardiac Society Guidelines and Medical Pra and Royal College of Physicians Clinical Effectiveness Guideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation Heart, February 1, 2001; 85(2): 133 - 142. [Full Text]
|
|
|
|
|
|
J. A. Cairns, P. Theroux, H. D. Lewis Jr., M. Ezekowitz, and T. W. Meade Antithrombotic Agents in Coronary Artery Disease Chest, January 1, 2001; 119 (2009): 228S - 252S. [Full Text] [PDF]
|
|
|
|
 |
|
 G. G Nenci and A. Minciotti Low molecular weight heparins for arterial thrombosis Vascular Medicine, November 1, 2000; 5(4): 251 - 258. [Abstract] [PDF]
|
|
|
|
|
|
D. L. Bhatt and E. J. Topol Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes JAMA, September 27, 2000; 284(12): 1549 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Goodman, M. Cohen, F. Bigonzi, E. P. Gurfinkel, D. R. Radley, V. Le Iouer, G. J. Fromell, C. Demers, A. G. G. Turpie, R. M. Califf, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the essence study J. Am. Coll. Cardiol., September 1, 2000; 36(3): 693 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Braunwald, E. M. Antman, J. W. Beasley, R. M. Califf, M. D. Cheitlin, J. S. Hochman, R. H. Jones, D. Kereiakes, J. Kupersmith, T. N. Levin, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina) J. Am. Coll. Cardiol., September 1, 2000; 36(3): 970 - 1062. [Full Text] [PDF]
|
|
|
|
|
|
M.E Bertrand, M.L Simoons, K.A.A Fox, L.C Wallentin, C.W Hamm, E McFadden, P.J de Feyter, G Specchia, and W Ruzyllo Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology: Recommendations of the Task Force of the European Society of Cardiology Eur. Heart J., September 1, 2000; 21(17): 1406 - 1432. [PDF]
|
|
|
|
|
|
E. M. Antman, M. Cohen, P. J. L. M. Bernink, C. H. McCabe, T. Horacek, G. Papuchis, B. Mautner, R. Corbalan, D. Radley, and E. Braunwald The TIMI Risk Score for Unstable Angina/Non-ST Elevation MI: A Method for Prognostication and Therapeutic Decision Making JAMA, August 16, 2000; 284(7): 835 - 842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Ohman, C. B. Granger, R. A. Harrington, and K. L. Lee Risk Stratification and Therapeutic Decision Making in Acute Coronary Syndromes JAMA, August 16, 2000; 284(7): 876 - 878. [Full Text] [PDF]
|
|
|
|
|
|
S. Kaul and P. K. Shah Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? J. Am. Coll. Cardiol., June 1, 2000; 35(7): 1699 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Meta-Analysis Confirms Benefit of Enoxaparin in Unstable Angina Journal Watch Emergency Medicine, December 1, 1999; 1999(1201): 4 - 4. [Full Text]
|
|
|
|
 |
|
 Low-Molecular-Weight Heparin Improves Outcomes in Unstable Coronary Syndromes Journal Watch (General), October 22, 1999; 1999(1022): 4 - 4. [Full Text]
|
|
|
|
|
|
E. M. Antman, C. H. McCabe, E. P. Gurfinkel, A. G. G. Turpie, P. J. L. M. Bernink, D. Salein, A. Bayes de Luna, K. Fox, J.-M. Lablanche, D. Radley, et al. Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non-Q-Wave Myocardial Infarction : Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B Trial Circulation, October 12, 1999; 100(15): 1593 - 1601. [Abstract] [Full Text] [PDF]
|
|